Clinical trial · Observational
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area.
NCT04529564CI-TRIAL-00079757completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- EAP patients
- description
- The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in Taiwan during 2018 to 2019.
Primary outcomes (2)
- measure
- Progression free survival (PFS)
- timeFrame
- time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (estimate assessed up to 3 years)
- description
- Defined as the time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (including metastatic disease) determined by physicians' assessment, metastatic recurrence or death (if no progression) or end of follow-up (for censored observations)
- measure
- Overall survival (OS)
- timeFrame
- time from durvalumab initiation date up to death or last date the patient was known to be alive (estimate assessed up to 5 years)
- description
- Defined as the time from durvalumab initiation date up to death or last date the patient was known to be alive (for censored observations).
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent or any locally required authorisation obtained from the patient prior to performing any protocol-related procedures 2. Adult of age ≥ 20 years at time of study entry 3. Patients must have been enrolled in one of the Pacific durvalumab EAPs Exclusion Criteria: 1\. Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP).
References
Publications (0)
Data not yet available
No reference posted for this study.